A5034730580- CAR-T cell therapy research
- Viral Infectious Diseases and Gene Expression in Insects
- CRISPR and Genetic Engineering
- RNA Interference and Gene Delivery
- Nanowire Synthesis and Applications
- Integrated Circuits and Semiconductor Failure Analysis
- Hepatitis C virus research
- Mathematical and Theoretical Epidemiology and Ecology Models
- Hepatitis B Virus Studies
- Silicon Carbide Semiconductor Technologies
Moffitt Cancer Center
2017-2024
University of Science and Technology Beijing
2023
CD33 and CD123 are expressed on the surface of human acute myeloid leukemia blasts other noncancerous tissues such as hematopoietic stem cells. On-target off-tumor toxicities may limit chimeric antigen receptor T cell therapies that target both CD123. To overcome this limitation, we developed bispecific CD33/CD123 (CAR) cells with an "AND" logic gate. We produced novel scFvs from monoclonal antibodies bound activated Screening CAR for cytotoxicity, cytokine production, proliferation was...
Abstract Chimeric antigen receptor (CAR) T cells have mediated exciting results for patients. The CAR is a novel antigen-receptor that includes an antigen-binding domain, derived from antibody, linked to intracellular cell activation domain. This 1st generation design worked well in vitro but poor vivo. Modification of the include co-stimulatory classified as 2nd design, achieved optimal persistence and tumor killing mice, which served rationale evaluation most common clinically evaluated...
Abstract The prototypical second-generation CD19-targeted CAR (chimeric antigen receptor) features a costimulatory domain, either CD28 or 41BB, with both designs achieving comparable clinical outcomes against B cell malignancies. However, application of T cells has outpaced the understanding their functions in vivo. We evaluated fully murine containing 41BB endodomain an immune competent B-ALL (B acute lymphoblastic leukemia) mouse model. Mouse imparted inferior survival to at stress-test...